{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:38:51Z","timestamp":1792798731780,"version":"4.5.0"},"reference-count":43,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T00:00:00Z","timestamp":1606262400000},"content-version":"unspecified","delay-in-days":24,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Katie Find a Cure Foundation","id":[{"id":"https:\/\/ror.org\/03xrx2656","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100020812","name":"Robert Steel Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100020812","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Kids Walk for Kids with Cancer NYC"},{"name":"Isabella Santos Foundation"},{"name":"Enid A. Haupt Endowed Chair"},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ymabs Therapeutics Inc."}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2020,10,16]]},"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Leukemia represents about 5% of all human cancers. Despite advances in therapeutics, a substantial number of patients succumb to the disease. Several subtypes of leukemia are inherently more resistant to treatment despite intensive chemotherapy or targeted therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Here we describe the generation of T cell engaging (CD3) bispecific antibodies (BsAbs) built on humanized IgG frameworks using the IgG(L)-scFv format against two targets expressed on acute lymphoblastic leukemia (ALL) and on acute myeloid leukemia (AML).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Each BsAb mediated potent anti-leukemia effect against ALL (CD19) and AML (CD33) in vitro and in xenograft models. Importantly, the CD19-specific BsAb (BC250) was effective against hematogenous spread preventing metastases to liver and kidney in mice bearing ALL and Burkitt\u2019s lymphoma xenografts. BC250 was more potent than the The Food and Drug Administration (FDA)-approved BsAb blinatumomab against ALL xenografts in vivo as measured by tumor bioluminescence and mouse survival. Furthermore, the combination of the CD19 and CD33 BsAbs in two xenograft models of mixed phenotype acute leukemia (biphenotypic and bilineal leukemia) was far superior than monotherapy with either of the BsAbs alone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Selective combinations of these leukemia-specific BsAb offer the potential to overcome tumor heterogeneity or clonal escape in the modern era of antibody-based T cell-driven immunotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2020-001626","type":"journal-article","created":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T15:51:38Z","timestamp":1606319498000},"page":"e001626","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":12,"title":["Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies"],"prefix":"10.1136","volume":"8","author":[{"given":"Sayed Shahabuddin","family":"Hoseini","sequence":"first","affiliation":[{"name":"Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8473-556X","authenticated-orcid":false,"given":"Madelyn","family":"Espinosa-Cotton","sequence":"additional","affiliation":[{"name":"Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-fen","family":"Guo","sequence":"additional","affiliation":[{"name":"Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nai-Kong V","family":"Cheung","sequence":"additional","affiliation":[{"name":"Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,11,25]]},"reference":[{"key":"2025100306250722000_8.2.e001626.1","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/16078454.2018.1549802","article-title":"Efficacy and safety of bispecific T-cell engager (BiTE) antibody blinatumomab for the treatment of relapsed\/refractory acute lymphoblastic leukemia and non-Hodgkin's lymphoma: a systemic review and meta-analysis","volume":"24","author":"Yu","year":"2019","journal-title":"Hematology"},{"key":"2025100306250722000_8.2.e001626.2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.064485"},{"key":"2025100306250722000_8.2.e001626.3","doi-asserted-by":"publisher","DOI":"10.1038\/nature10738"},{"key":"2025100306250722000_8.2.e001626.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1106968"},{"key":"2025100306250722000_8.2.e001626.5","doi-asserted-by":"crossref","first-page":"8441","DOI":"10.18632\/oncotarget.23878","article-title":"Mixed phenotype acute leukemia contains heterogeneous genetic mutations by next-generation sequencing","volume":"9","author":"Quesada","year":"2018","journal-title":"Oncotarget"},{"key":"2025100306250722000_8.2.e001626.6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-665547"},{"key":"2025100306250722000_8.2.e001626.7","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12320"},{"key":"2025100306250722000_8.2.e001626.8","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/pbc.25953","article-title":"Lineage switch in MLL-rearranged infant leukemia following CD19-Directed therapy","volume":"63","author":"Rayes","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"2025100306250722000_8.2.e001626.9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.3247"},{"key":"2025100306250722000_8.2.e001626.10","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-1020"},{"key":"2025100306250722000_8.2.e001626.11","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0146-z"},{"key":"2025100306250722000_8.2.e001626.12","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25791"},{"key":"2025100306250722000_8.2.e001626.13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-3010"},{"key":"2025100306250722000_8.2.e001626.14","doi-asserted-by":"publisher","DOI":"10.4161\/21645515.2014.982993"},{"key":"2025100306250722000_8.2.e001626.15","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.1016\/j.bbmt.2014.11.290","article-title":"Myeloid Derived Suppressor Cells (MDSC)-like Acute Myeloid Leukemia (AML) Cells Are Associated with Resistance to Cytotoxic Effects of Autologous (Auto) T-Lymphocytes (CTLs)","volume":"21","author":"Mehta","year":"2015","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"2025100306250722000_8.2.e001626.16","doi-asserted-by":"publisher","DOI":"10.21037\/tcr.2016.08.15"},{"key":"2025100306250722000_8.2.e001626.17","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax1315","article-title":"Interdomain spacing and spatial configuration drive the potency of IgG-[L]-scFv T cell bispecific antibodies","volume":"12","author":"Santich","year":"2020","journal-title":"Sci Transl Med"},{"key":"2025100306250722000_8.2.e001626.18","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/icb.1991.58","article-title":"Preparation and characterization of a chimeric CD19 monoclonal antibody","volume":"69 (Pt 6)","author":"Zola","year":"1991","journal-title":"Immunol Cell Biol"},{"key":"2025100306250722000_8.2.e001626.19","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.52"},{"key":"2025100306250722000_8.2.e001626.20","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.4049\/jimmunol.148.9.2756","article-title":"Humanized OKT3 antibodies: successful transfer of immune modulating properties and idiotype expression","volume":"148","author":"Woodle","year":"1992","journal-title":"J Immunol"},{"key":"2025100306250722000_8.2.e001626.21","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0230-T"},{"key":"2025100306250722000_8.2.e001626.22","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29007"},{"key":"2025100306250722000_8.2.e001626.23","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017014373"},{"key":"2025100306250722000_8.2.e001626.24","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/cwq220"},{"key":"2025100306250722000_8.2.e001626.25","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.5858\/arpa.2017-0218-RA","article-title":"Mixed-Phenotype acute leukemia: diagnostic criteria and pitfalls","volume":"141","author":"Charles","year":"2017","journal-title":"Arch Pathol Lab Med"},{"key":"2025100306250722000_8.2.e001626.26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-018192"},{"key":"2025100306250722000_8.2.e001626.27","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/jco.2013.31.15_suppl.3048","article-title":"Pharmacokinetics (pK) of blinatumomab and its clinical implications","volume":"31","author":"Wu","year":"2013","journal-title":"JCO"},{"key":"2025100306250722000_8.2.e001626.28","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1267891","article-title":"Overcoming resistance to HER2-targeted therapy with a novel HER2\/CD3 bispecific antibody","volume":"6","author":"Lopez-Albaitero","year":"2017","journal-title":"Oncoimmunology"},{"key":"2025100306250722000_8.2.e001626.29","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-18-0026"},{"key":"2025100306250722000_8.2.e001626.30","doi-asserted-by":"crossref","unstructured":"Cheng M et al . Successful engineering of a highly potent single-chain variable-fragment (scFv) bispecific antibody to target disialoganglioside (GD2) positive tumors. Oncoimmunology 5, e1168557 2016.","DOI":"10.1080\/2162402X.2016.1168557"},{"key":"2025100306250722000_8.2.e001626.31","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2764"},{"key":"2025100306250722000_8.2.e001626.32","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3390\/antib5010006","article-title":"Development of PF-06671008, a highly potent anti-P-cadherin\/anti-CD3 bispecific DART molecule with extended half-life for the treatment of cancer","volume":"5","author":"Root","year":"2016","journal-title":"Antibodies"},{"key":"2025100306250722000_8.2.e001626.33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0350"},{"key":"2025100306250722000_8.2.e001626.34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.5929"},{"key":"2025100306250722000_8.2.e001626.35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"2025100306250722000_8.2.e001626.36","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0201-9"},{"key":"2025100306250722000_8.2.e001626.37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-384388"},{"key":"2025100306250722000_8.2.e001626.38","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"key":"2025100306250722000_8.2.e001626.39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222"},{"key":"2025100306250722000_8.2.e001626.40","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.3247"},{"key":"2025100306250722000_8.2.e001626.41","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.ctrv.2015.10.008","article-title":"The use of combinations of monoclonal antibodies in clinical oncology","volume":"41","author":"Henricks","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"2025100306250722000_8.2.e001626.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2011.09.003"},{"key":"2025100306250722000_8.2.e001626.43","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1080\/21645515.2019.1675459","article-title":"CIMT 2019: report on the 17th annual meeting of the association for cancer immunotherapy","volume":"16","author":"Beck","year":"2020","journal-title":"Hum Vaccin Immunother"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2020-001626","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T13:25:17Z","timestamp":1759497917000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2020-001626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":43,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,11,25]]},"published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1136\/jitc-2020-001626"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2020-001626","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11]]}}}